Intelligene (7832.TWO) Akcie Kurz

Intelligene Inc develops innovative RNA gene therapy drugs using siRNA gene compilation technology for treating pneumonia and influenza. The company focuses on research and development of nucleic acid drugs targeting all cases of pneumonia and influenza. Intelligene Inc is a Taiwan-based company with 20 full-time employees operating in the pharmaceutical industry. The company's primary revenue comes from the development and potential commercialization of its RNA-based gene therapy drugs. Intelligene Inc is engaged in the research and development of innovative nucleic acid drugs based on siRNA technology for pneumonia and influenza treatments. The firm aims to provide novel therapeutic solutions for respiratory diseases through its proprietary technology. Intelligene Inc's products target medical professionals and healthcare institutions seeking advanced treatments for pneumonia and influenza. The company's research focuses on developing drugs that address all cases of these respiratory conditions. The firm operates within the pharmaceutical sector with a specific emphasis on RNA-based therapies for respiratory illnesses.